Prognostic Role of OX40, LAG-3, TIM-3 and PD-L1 Expression in Bone and Soft Tissue Sarcomas

被引:1
作者
Inci, Bediz Kurt [1 ]
Acar, Elif [2 ]
Gurler, Fatih [1 ]
Ilhan, Ayseguel [3 ]
Yildiz, Fatih [3 ]
Ardic, Fisun [4 ]
Oksuzoglu, Berna [3 ]
Ozdemir, Nuriye [1 ]
Ozet, Ahmet [1 ]
Esendagli, Guldal [2 ]
Yazici, Ozan [1 ]
机构
[1] Gazi Univ Hosp, Med Oncol Dept, TR-2906500 Ankara, Turkiye
[2] Gazi Univ Hosp, Pathol Dept, TR-2906500 Ankara, Turkiye
[3] Dr Abdurrahman Yurtaslan Ankara Oncol Hosp, Med Oncol Dept, TR-2906200 Ankara, Turkiye
[4] Dr Abdurrahman Yurtaslan Ankara Oncol Hosp, Pathol Dept, TR-2906200 Ankara, Turkiye
关键词
sarcoma; OX40; T & Idot; M-3; LAG-3; PD-L1; MOLECULES LAG-3; OPEN-LABEL; T-CELLS; CANCER; OX-40; CHEMOTHERAPY;
D O I
10.3390/jcm13123620
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: The current study aims to evaluate the OX40, TIM-3, LAG-3, and PD-L1 targeted pathways in the regulation of T-cell activity in sarcoma patients to determine their relationship with overall survival (OS). Method: This study included one hundred and eleven patients with bone and soft tissue sarcoma diagnosed in two centers between 2010 and 2020. OX40, LAG-3, TIM-3 and PD-L1 expression levels were evaluated immunohistochemically from pathology preparations. Results: PD-L1 staining was detected in tumor cells, OX40, LAG-3, TIM-3 staining was detected in inflammatory cells in tumor tissue. In univariate analysis, no significant relationship was found between OX40, TIM-3, LAG-3, and PD-L1 staining and overall survival (respectively: p = 0.12, p = 0.49, p = 0.31, p = 0.95). When grade and stage at diagnosis, which were found to be significant in univariate analysis, along with OX-40, TIM-3, LAG-3, and PD-L1, were evaluated in multivariate analysis, a positive effect of OX-40 staining on overall survival was determined (p = 0.009). Considering the correlation between PDL-1 and OX40, TIM-3, and LAG-3 staining, a significant positive correlation was found between PDL-1 and TIM-3 and LAG-3 staining (respectively; p = 0.002, p = 0.001). Conclusions: There was no significant relationship between the PDL-1 staining percentage of tumor cells and OX40, TIM-3, and LAG-3 staining in inflammatory cells with the OS of sarcoma patients. However, detecting a significant positive correlation between PDL-1 staining and TIM-3 and LAG-3 staining also holds promise for finding effective targetable combination therapies that can prolong survival in sarcoma patients in the future.
引用
收藏
页数:12
相关论文
共 45 条
[1]   Clinical Significance of Expression of Immunoadjuvant Molecules (LAG-3, TIM-3, OX-40) in Neoadjuvant Chemotherapy for Breast Cancer [J].
Asano, Yuka ;
Kashiwagi, Shinichiro ;
Takada, Koji ;
Ishihara, Sae ;
Goto, Wataru ;
Morisaki, Tamami ;
Shibutani, Masatsune ;
Tanaka, Hiroaki ;
Hirakawa, Kosei ;
Ohira, Masaichi .
ANTICANCER RESEARCH, 2022, 42 (01) :125-136
[2]   Analysis of Real-World Data to Investigate the Impact of Race and Ethnicity on Response to Programmed Cell Death-1 and Programmed Cell Death-Ligand 1 Inhibitors in Advanced Non-Small Cell Lung Cancers [J].
Ayers, Kristin L. ;
Mullaney, Tommy ;
Zhou, Xiang ;
Liu, Jane J. ;
Lee, Kyeryoung ;
Ma, Meng ;
Jones, Scott ;
Li, Li ;
Redfern, Arielle ;
Jappe, Whitney ;
Liu, Zongzhi ;
Goldsweig, Howard ;
Yadav, Kamlesh K. ;
Hahner, Nicholas ;
Dietz, Matthew ;
Zimmerman, Michelle ;
Prentice, Tony ;
Newman, Scott ;
Veluswamy, Rajwanth ;
Wisnivesky, Juan ;
Hirsch, Fred R. ;
Oh, William K. ;
Li, Shuyu D. ;
Schadt, Eric E. ;
Chen, Rong .
ONCOLOGIST, 2021, 26 (07) :E1226-E1239
[3]   PDL1 expression is a poor- prognosis factor in soft-tissue sarcomas [J].
Bertucci, Francois ;
Finetti, Pascal ;
Perrot, Delphine ;
Leroux, Agnes ;
Collin, Francoise ;
Le Cesned, Axel ;
Coindre, Jean-Michel ;
Blay, Jean-Yves ;
Birnbaum, Daniel ;
Mamessier, Emilie .
ONCOIMMUNOLOGY, 2017, 6 (03)
[4]   Emerging targets in cancer immunotherapy [J].
Burugu, Samantha ;
Dancsok, Amanda R. ;
Nielsen, Torsten O. .
SEMINARS IN CANCER BIOLOGY, 2018, 52 :39-52
[5]   CONGRATS-combination of nivolumab plus relatlimab in patients with advanced or metastatic soft-tissue sarcoma: A proof-of-concept randomized phase II study [J].
Ceruso, M. Spalato ;
Albert, S. ;
Italiano, A. ;
Toulmonde, M. ;
Cousin, S. ;
Grellety, T. ;
Blay, J-Y. ;
Verret, B. ;
Auzanneau, C. ;
Valade, V. ;
Poignie, L. ;
Lortal, B. ;
Kind, M. ;
Le Loarer, F. ;
Pulido, M. .
ANNALS OF ONCOLOGY, 2022, 33 (07) :S1243-S1243
[6]   Targeting Programmed Cell Death-1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy [J].
Constantinidou, Anastasia ;
Alifieris, Constantinos ;
Trafalis, Dimitrios T. .
PHARMACOLOGY & THERAPEUTICS, 2019, 194 :84-106
[7]   Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials [J].
D'Angelo, Sandra P. ;
Mahoney, Michelle R. ;
Van Tine, Brian A. ;
Atkins, James ;
Milhem, Mohammed M. ;
Jahagirdar, Balkrishna N. ;
Antonescu, Cristina R. ;
Horvath, Elise ;
Tap, William D. ;
Schwartz, Gary K. ;
Streicher, Howard .
LANCET ONCOLOGY, 2018, 19 (03) :416-426
[8]   Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment [J].
D'Angelo, Sandra P. ;
Shoushtari, Alexander N. ;
Agaram, Narasimhan P. ;
Kuk, Deborah ;
Qin, Li-Xuan ;
Carvajal, Richard D. ;
Dickson, Mark A. ;
Gounder, Mrinal ;
Keohan, Mary Louise ;
Schwartz, Gary K. ;
Tap, William D. .
HUMAN PATHOLOGY, 2015, 46 (03) :357-365
[9]   Expression of lymphocyte immunoregulatory biomarkers in bone and soft-tissue sarcomas [J].
Dancsok, Amanda R. ;
Setsu, Nokitaka ;
Gao, Dongxia ;
Blay, Jean-Yves ;
Thomas, David ;
Maki, Robert G. ;
Nielsen, Torsten O. ;
Demicco, Elizabeth G. .
MODERN PATHOLOGY, 2019, 32 (12) :1772-1785
[10]   Immunotherapy of heterogenous sarcomas: questions and strategies [J].
Dufresne, Armelle ;
Meurgey, Alexandra ;
Brahmi, Mehdi .
CURRENT OPINION IN ONCOLOGY, 2019, 31 (04) :304-309